Novartis AG
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Vasant Narasimhan
- Full Time Employees
- 75,267
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Lichtstrasse 35 Basel BS Switzerland 4056
- IPO Date
- Nov 7, 1996
- CIK
- 0001114448
- Website
- novartis.com
- Similar Companies
- Business
- Novartis AG (NVS), a Swiss multinational pharmaceutical company headquartered in Basel and founded in 1996 through the merger of Ciba-Geigy and Sandoz, develops, manufactures and markets innovative medicines focused on oncology, immunology, neuroscience, cardiovascular, renal and metabolic diseases; key products include Kisqali (ribociclib) for breast cancer, Cosentyx (secukinumab) for psoriasis and arthritis, Entresto (sacubitril/valsartan) for heart failure, Kesimpta (ofatumumab) for multiple sclerosis, Pluvicto for prostate cancer, Scemblix (asciminib) for leukemia, Leqvio for cholesterol reduction, Zolgensma for spinal muscular atrophy, and radioligand therapies alongside gene and cell therapies like Kymriah (tisagenlecleucel). The company operates globally with major research hubs in Cambridge, Massachusetts, and expanded facilities in the US including a new San Diego research center planned for 2028-2029 and manufacturing investments totaling over $23 billion across 10 sites to achieve 100% end-to-end US production of key medicines by end-2025; it spun off its generics division Sandoz in October 2023 and Alcon eye care in 2019 to sharpen focus on high-value innovative medicines. Recent strategic moves include the October 2025 $12 billion acquisition of Avidity Biosciences to bolster RNA therapeutics for neuromuscular diseases, completion of Tourmaline Bio acquisition for pipeline enhancement, February 2025 purchase of Anthos Therapeutics for $925 million in cardiovascular assets, April 2025 agreement to acquire Regulus Therapeutics for up to $1.7 billion in microRNA therapies, plus licensing deals with Argo Biopharma, Arvinas, Arrowhead Pharmaceuticals and Dren Bio exceeding $17 billion in potential value to offset patent losses and drive 5-6% compound annual sales growth through 2030.
Company News
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
Critical Analysis: Redhill Biopharma (NASDAQ:RDHL) versus Novartis (NYSE:NVS)
Novartis halts ALS drug development after mid-stage trial failure
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits?
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
Legend Biotech taps Novartis veteran Zhang as CEO
Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
Novartis: More Pain on the Way?
Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning
Focus: Novartis investors turn spotlight on M&A after trial setbacks
Here Are Thursday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Amgen, AngloGold Ashanti, Caterpillar, Chewy, Meta Platforms, Novartis, NVIDIA, SK hynix, and More
First Look: Apple Unveils Foldable iPhone, Google Invests $15B in AI
Major Novartis shareholder calls for board shake-up after drug trial setbacks
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
Novartis Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Novartis (NVS)
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling